| Accession |
PRJCA016015 |
| Title |
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of INL1 (Trientine) in Patients with Heart Failure and Reduced Ejection Fraction |
| Relevance |
Medical |
| Data types |
Biomarker data and Metabolism data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the efficacy of INL1 (trientine) as compared to placebo in patients with heart failure (HF) (New York Heart Association [NYHA] functional class II and III) and reduced left ventricular ejection fraction (LVEF < 40%) at 12 weeks. To evaluate the safety and tolerability of INL1 (trientine) as compared to placebo in HF patients. To characterize the pharmacokinetics (PK) of INL1 over 12 weeks of treatment. |
| Sample scope |
Multiisolate |
| Release date |
2023-05-24 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Jing
Yu (yujing2304@126.com)
|
| Organization |
Lanzhou University Second Hospital |
| Submission date |
2023-01-04 |
